Abstract: Objective To investigate the clinical efficacy of peg-IFNα and ribavirin combination in treating patients with chronic hepatitis C（CHC） and genotype one and six infection. Methods A total of 246 patients with CHC were enrolled in this study,and the patients were randomly divided into observation group （n=123） and control group （n=123）,receiving peg-IFNα-2b 80 μg,or peg-IFNα-2a 180 μg subcutaneously once a week,respectively,and the patients with CHC in both groups received ribavirin orally for 48 weeks. All patients were followed-up for 24 weeks after discontinuation of the regimen. Serum HCV RNA and HCV genotypes were detected routinely by Abbott RealTime HCV Genotype II kits. Results At baseline, the genotype one of HCV infection in the observation and control groups were 84.6% and 87.8%,and genotype six infection were 15.4% and 12.2% （P>0.05）,serum HCV RNA levels were（7.17±0.89） lg copies/ml and （7.19±0.88） lg copies/ml,white blood cell counts were （6.6±1.3）×10⁹/L and （6.6±1.5）×10⁹/L,platelet counts were （154.1±21.1）×10⁹/L and （157.2±19.2）×10⁹/L,serum ALT levels were（83.4±26.3） U/L and （80.3±29.4） U/L,all without significant differences （P>0.05）;the rapid virologic response（RVR）,early virologic response（EVR）,end-treatment virologic response（ETVR） and sustained virologic response rates（SVR） in the observation group were 45.5%, 82.1%,83.7% and 85.4%,no significant differences as compared to 43.1%,78.9%,79.7% and 78.0%,respectively in the control （P>0.05）,and the relapse rates in the two groups were 14.6% and 22.0%（P>0.05）;during the injection of interferon-α,there were no significant differences as compared to the side effects such as the fever （58.5% vs. 61.0%）,muscle aches（48.8% vs. 51.2%）,fatigue （41.5% vs. 44.7%）,headaches （30.9% vs. 34.1%）,anorexia（25.2% vs. 30.1%）,hair loss （26.8% vs. 30.9%）,insomnia（20.3% vs. 25.2%）,leukopenia（27.6% vs. 31.7%）,declined erythrocyte counts（23.6% vs. 28.5%）,thrombocytopenia （13.8% vs. 17.9%） and serum T3/T4/TSH level abnormal （8.9% vs. 10.6%,all P>0.05）. Conclusions Application of peg-IFNα-2b and peg-IFNα-2a show similar efficacy and safety in the treatment of patients with CHC with genotype 1/6 infection,which is worthy of further clinical observation.

Key words: Chronic hepatitis C, Peg-IFNα-2b, Peg-IFNα-2a, Genotype 1/6, Therapy